133 related articles for article (PubMed ID: 22176629)
1. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers.
Krishna G; Ma L; Prasad P; Moton A; Martinho M; O'Mara E
Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):1-10. PubMed ID: 22176629
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects.
Hoch M; Hoever P; Alessi F; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Mar; 69(3):523-32. PubMed ID: 22990330
[TBL] [Abstract][Full Text] [Related]
4. A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver.
Kumagai Y; Fujita T; Maeda M; Sasaki Y; Nagaoka M; Huang J; Takenaka T; Kawai M
J Clin Pharmacol; 2020 Jun; 60(6):702-710. PubMed ID: 32026490
[TBL] [Abstract][Full Text] [Related]
5. An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers.
Tomkinson HK; Kemp JV; Wollseifen T; Morris T; Oliver SD
Clin Ther; 2010 Jul; 32(7):1372-86. PubMed ID: 20678684
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants.
Miao S; Bekker P; Armas D; Lor M; Han Y; Webster K; Trivedi A
Clin Pharmacol Drug Dev; 2024 May; 13(5):517-533. PubMed ID: 38423992
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet does not affect the activity of cytochrome P450 3A enzymes, a metabolic pathway for common immunosuppressive agents : a randomized, open-label, crossover, single-centre study in healthy volunteers.
Padhi D; Salfi M; Emery M
Drugs R D; 2008; 9(5):335-43. PubMed ID: 18721002
[TBL] [Abstract][Full Text] [Related]
8. Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity.
Stoll F; Burhenne J; Lausecker B; Weiss J; Thomsen T; Haefeli WE; Mikus G
J Clin Pharmacol; 2013 Nov; 53(11):1199-204. PubMed ID: 23939663
[TBL] [Abstract][Full Text] [Related]
9. PBPK modeling of CYP3A and P-gp substrates to predict drug-drug interactions in patients undergoing Roux-en-Y gastric bypass surgery.
Chen KF; Chan LN; Lin YS
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):493-512. PubMed ID: 32710209
[TBL] [Abstract][Full Text] [Related]
10. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects.
Prueksaritanont T; Vega JM; Rogers JD; Gagliano K; Greenberg HE; Gillen L; Brucker MJ; McLoughlin D; Wong PH; Waldman SA
J Clin Pharmacol; 2000 Nov; 40(11):1274-9. PubMed ID: 11075313
[TBL] [Abstract][Full Text] [Related]
12. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.
Krishna G; Sansone-Parsons A; Kantesaria B
Curr Med Res Opin; 2007 Jun; 23(6):1415-22. PubMed ID: 17559737
[TBL] [Abstract][Full Text] [Related]
13. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin.
Garg V; Chandorkar G; Farmer HF; Smith F; Alves K; van Heeswijk RP
J Clin Pharmacol; 2012 Oct; 52(10):1566-73. PubMed ID: 22162542
[TBL] [Abstract][Full Text] [Related]
14. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
15. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Kokudai M; Inui N; Takeuchi K; Sakaeda T; Kagawa Y; Watanabe H
J Clin Pharmacol; 2009 May; 49(5):568-73. PubMed ID: 19398603
[TBL] [Abstract][Full Text] [Related]
16. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin.
Lilja JJ; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Oct; 68(4):384-90. PubMed ID: 11061578
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
[TBL] [Abstract][Full Text] [Related]
18. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects.
Falcão A; Pinto R; Nunes T; Soares-da-Silva P
Epilepsy Res; 2013 Sep; 106(1-2):244-9. PubMed ID: 23726291
[TBL] [Abstract][Full Text] [Related]
19. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
20. Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
Chung E; Nafziger AN; Kazierad DJ; Bertino JS
Clin Pharmacol Ther; 2006 Apr; 79(4):350-61. PubMed ID: 16580903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
